Elekta AB stock (SE0000163628): Included in OMX Stockholm ESG Index

Elekta AB appears in the OMX Stockholm Benchmark ESG Responsible Gross Index weighting as of May 13, 2026, highlighting its sustainability focus amid growing demand for radiation therapy solutions.

Elekta AB, a leading provider of precision radiation medicine solutions, is featured in the OMX Stockholm Benchmark ESG Responsible Gross Index weighting updated on May 13, 2026. The index, which tracks ESG-compliant companies, lists Elekta AB ser. B (EKTA B) at position 33, signaling strong environmental, social, and governance credentials. This placement underscores Elekta's role in sustainable healthcare innovation for US investors tracking global medtech exposure.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta AB (publ)
• Sector/industry: Medical devices / Radiation therapy
• Headquarters/country: Stockholm, Sweden
• Core markets: North America, Europe, Asia
• Key revenue drivers: Oncology systems, software, service
• Home exchange/listing venue: Nasdaq Stockholm (EKTA B)
• Trading currency: SEK

Elekta AB: core business model

Elekta AB develops and sells clinical solutions for treating cancer and brain disorders using radiation therapy and radiosurgery. Its portfolio includes linear accelerators like Versa HD and Leksell Gamma Knife, alongside software for treatment planning and oncology information systems. The company operates globally, with significant US market presence through installations in major cancer centers, according to Elekta.com as of 05/13/2026.

Revenue stems primarily from equipment sales, upgrades, and long-term service contracts. Elekta emphasizes precision medicine to minimize side effects, aligning with rising demand for non-invasive cancer treatments. For US investors, Elekta offers exposure to the expanding $10B+ US radiation oncology market.

Main revenue and product drivers for Elekta AB

Oncology systems account for the bulk of revenue, driven by products like Elekta Unity (MRI-guided radiotherapy) and Harmony linear accelerators. Service and software segments provide recurring income, with digital solutions like MOSAIQ OIS supporting over 4,000 cancer centers worldwide. North America contributes around 40% of sales, per company reports, making it relevant for US portfolios amid aging demographics boosting cancer care needs.

Recent index inclusion in OMXSBESGGI reflects Elekta's ESG integration, including sustainable manufacturing and diversity initiatives, as detailed in the Nasdaq OMX index weighting as of 05/13/2026.

Industry trends and competitive position

The radiation therapy market is projected to grow at 6-7% CAGR through 2030, fueled by minimally invasive procedures and AI integration. Elekta competes with Varian Medical Systems (acquired by Siemens Healthineers) and Accuray, differentiating via MRI-Linac tech and brachytherapy offerings. Its ESG index status enhances appeal to sustainable funds, per IndexBox market overview.

Why Elekta AB matters for US investors

With heavy US revenue reliance and listings in major indices, Elekta provides diversified medtech exposure without direct Nasdaq listing. Its tech supports key US providers like MD Anderson, tying into the $200B+ US oncology spend. ESG weighting adds stability for long-term holders amid tariff concerns on EU medtech.

Conclusion

Elekta AB's inclusion in the OMX Stockholm ESG index highlights its sustainable positioning in radiation oncology. Ongoing innovation in precision therapy supports revenue growth potential, while global reach benefits US investors seeking international healthcare plays. Market dynamics and competition remain key factors to monitor.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.